Skip to content

Coaptite Injectable Implant

by Merz North America, Inc.

PMA P040047

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

1 ongoing

This device is named in the recall

Documents

PMA P040047↗

FDA record

Trust

Unverified

Source FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP040047 Date10 Nov 2005ApprovedStatusActive

Official records

From the FDA record

FDA PMA P040047

Received by the FDA
9 Dec 2004
FDA decision
10 Nov 2005
FDA review time
336 days from receipt to decision
Docket number
05M-0477
Approval order statement, verbatim
APPROVAL FOR COAPTITE. THE DEVICE IS INDICATED FOR SOFT TISSUE AUGMENTATION IN THE TREATMENT OF STRESS URINARY INCONTINENCE (SUI) DUE TO INTRINSIC SPHINCTER DEFICIENCY (ISD) IN ADULT FEMALES.

From the FDA PMA record P040047 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Recalls

1 recall · 1 ongoing · FDA

    • Ongoing Z-0401-2021 FDA Class II initiated 30 Sep 2020

    The Instructions for Use (IFU) updated 03/02/2020 does not match data listed in the post-approval study.

Timeline

2 dated events

  1. Approved FDA PMA P040047
  2. Recall initiated FDA recalls Z-0401-2021

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Trade name
Coaptite
Generic name
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
PMA number
FDA product code
LNM
Device class
Class III
Advisory committee
Gastroenterology, Urology
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Coaptite Injectable Implant is a bulking agent classified as an Agent, Bulking, Injectable for Gastro-Urology Use, designed for soft tissue augmentation. It is intended to treat stress urinary incontinence (SUI) caused by intrinsic sphincter deficiency (ISD) in adult females by reinforcing the urethral support mechanism.

This device is supplied as a sterile, injectable implant and is regulated under FDA Premarket Approval (PMA P040047). Administered via urological procedures, it is intended for single-use per patient application. No MRI safety data or reusable configurations are specified, and storage conditions align with standard sterile injectable protocols.

Devices cleared under P040047

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P040047
UDI-DISize and differences
Coaptite 8005P10
Merz North America, Inc.
M0068903000 / 8005P1008714729804796
Total Volume 1 mL
On the market

Similar devices

Other devices filed under FDA product code LNM (Agent, Bulking, Injectable For Gastro-Urology Use).

Other devices from Merz North America, Inc.

See all devices from Merz North America, Inc. →